Watermark
  Back to Search Results

AdvanTIG-101

Completed

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

AdvanTIG-101

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT05267054

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20220360

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan